Apolipoprotein panel improved risk prediction after acute coronary syndrome
In trial participants receiving statins, an apolipoprotein panel predicted cardiovascular events and death better than a lipid panel. Further validation is needed.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Among patients receiving statins after acute coronary syndrome, the apolipoprotein panel predicted cardiovascular events and death better than the lipid panel. Combining the panels improved prediction further. Higher predicted cardiovascular risk also corresponded to greater estimated benefit from alirocumab. These findings concern prediction within this trial sample and require further validation.
The authors call for further validation. The abstract alone cannot establish how well the approach would work in other patient populations.
What researchers found
Major adverse cardiovascular event prediction
Apolipoprotein versus lipid panel; AUC over a median follow-up of 2.9 years.
Reading the prediction score
The area under the curve (AUC) measures how well a model distinguishes participants who later have an event from those who do not. Higher values indicate better discrimination; they are not event probabilities, percentage accuracy, or treatment-related risk reductions.
Estimating treatment benefit
The researchers also modeled who might benefit more from alirocumab. Higher risk estimated from the apolipoprotein panel predicted greater benefit, but the abstract does not show that using the panel to guide treatment improves outcomes.
The original publication
Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.
Reijnders E, Bossuyt PM, Jukema JW et al.
Arterioscler Thromb Vasc Biol · 2025
- PubMed ID
- 40995631
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.